symbol |
EIDx |
会社名 | Eidos Therapeutics Inc (エイドス・セラピュ―ティクス) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Major Pharmaceuticals
|
業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連(Health Care)
|
概要 |
事業概要 Eidos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company’s product candidate AG10 is an orally-administered small molecule designed to potently stabilize tetrameric TTR thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood preventing the formation of amyloid and halting progression of the disease. エイドス・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、希少疾患に対する治療薬の開発・商業化に従事する。同社はトランスサイレチン(TTR)やアミドイロ―シス(ATTR)によって引き起こされる疾患に対する治療薬の開発に焦点を当てる。本社所在地はカリフォルニア州サンフランシスコ。
|
本社所在地 | 101 Montgomery Street Suite 2550 San Francisco CA 94104 USA |
代表者氏名 | Jonathan C. Fox ジョナサン・フォックス |
代表者役職名 | President chief medical officer |
電話番号 | +1 650-391-9740 |
設立年月日 | 41487 |
市場名 | NASDAQ National Market System |
ipoyear | 2018年 |
従業員数 | - |
url | www.eidostx.com |
nasdaq_url | https://www.nasdaq.com/symbol/eidx |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -25.32500 |
終値(lastsale) | 10.05 |
時価総額(marketcap) | 369357871.35 |
時価総額 | 時価総額(百万ドル) 358.33220 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) 181.64320 |
当期純利益 | 当期純利益(百万ドル) -34.08400 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Eidos Therapeutics Inc revenues was not reported. Net loss increased from $4.1M to $26.2M. Higher net loss reflects Research and development - Balan increase from $3.2M to $11.2M (expense) Loss on extinguishment of debt increase from $0K to $6.7M (expense) General and administrative increase from $831K to $3.9M (expense). |